$KAYS
Kaya Holdings Inc Stock $kays

$kays Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000190359623000916 Filed on November 20, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q4
Revenue	$33.92K	$59.01K	$128.6K
YoY Change	-73.62%	-65.88%	-35.6%
Cost Of Revenue	$22.94K	$22.09K	$42.74K
YoY Change	-46.33%	-63.05%	-21.65%
Gross Profit	$10.98K	$36.92K	$85.82K
YoY Change	-87.21%	-67.38%	-40.85%
Gross Profit Margin	32.37%	62.57%	66.75%
Selling, General & Admin	$330.1K	$310.0K	$928.9K
YoY Change	-64.47%	-19.07%	101.34%
% of Gross Profit	3006.19%	839.59%	1082.43%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$1.850K	$0.00	$4.100K
YoY Change	-54.88%	-100.0%	-85.77%
% of Gross Profit	16.85%	0.0%	4.78%
Operating Expenses	$330.1K	$313.1K	$928.9K
YoY Change	-64.47%	-18.28%	101.35%
Operating Profit	-$319.1K	-$276.1K	-$843.1K
YoY Change	-62.15%	2.32%	166.57%
Interest Expense	$511.2K	$2.070M	$2.591M
YoY Change	-80.27%	-128.91%	-10.36%
% of Operating Profit
Other Income/Expense, Net	-$82.27K	$2.377M
YoY Change		-133.28%
Pretax Income	$224.2K	$2.101M	$1.748M
YoY Change	-87.18%	-128.34%	-34.04%
Income Tax	$4.220K	$5.270K	$16.51K
% Of Pretax Income	1.88%	0.25%	0.94%
Net Earnings	$241.7K	$2.096M	$1.809M
YoY Change	-86.64%	-128.26%	-14.52%
Net Earnings / Revenue	712.5%	3551.44%	1406.81%
Basic Earnings Per Share
Diluted Earnings Per Share	$0.01	$0.09	$0.11
COMMON SHARES
Basic Shares Outstanding	22.17M shares	22.17M shares	14.72M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$29.11K	$60.00K	$18.33K
YoY Change	58.81%	48.48%	-96.76%
Cash & Equivalents	$29.11K	$60.27K	$18.33K
Short-Term Investments
Other Short-Term Assets	$58.59K	$50.00K	$28.16K
YoY Change	108.06%	257.91%	101.57%
Inventory	$9.259K	$13.26K	$11.99K
Prepaid Expenses	$58.59K	$49.76K	$28.16K
Receivables
Other Receivables
Total Short-Term Assets	$96.96K	$123.3K	$58.48K
YoY Change	65.8%	48.38%	-90.74%
LONG-TERM ASSETS
Property, Plant & Equipment	$24.88K	$26.79K	$552.8K
YoY Change	-95.5%	-95.19%	-3.82%
Goodwill	$23.68K		$22.19K
YoY Change	6.73%
Intangibles
YoY Change
Long-Term Investments	$23.68K	$20.00K	$22.19K
YoY Change	6.71%	-9.71%	-11.31%
Other Assets	$40.48K	$40.01K	$27.18K
YoY Change	48.96%	-56.38%	-66.92%
Total Long-Term Assets	$118.9K	$107.3K	$784.8K
YoY Change	-84.85%	-87.79%	-16.31%
TOTAL ASSETS
Total Short-Term Assets	$96.96K	$123.3K	$58.48K
Total Long-Term Assets	$118.9K	$107.3K	$784.8K
Total Assets	$215.9K	$230.6K	$843.2K
YoY Change	-74.4%	-76.02%	-46.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.104M	$1.020M	$1.235M
YoY Change	-10.57%	587.54%	16.46%
Accrued Expenses	$2.400M	$2.210M	$1.853M
YoY Change	29.53%	31.14%	50.3%
Deferred Revenue
YoY Change
Short-Term Debt	$124.3K	$110.0K	$9.310K
YoY Change	1235.23%	1081.53%	0.0%
Long-Term Debt Due	$125.0K	$109.3K	$240.3K
YoY Change	-47.98%	17.11%	861.16%
Total Short-Term Liabilities	$7.405M	$7.771M	$10.42M
YoY Change	-28.92%	-39.66%	28.78%
LONG-TERM LIABILITIES
Long-Term Debt	$8.061M	$7.950M	$7.429M
YoY Change	8.51%	8.61%	3.4%
Other Long-Term Liabilities	$500.0K	$500.0K	$600.1K
YoY Change	-16.68%	-21.37%	-14.6%
Total Long-Term Liabilities	$8.561M	$8.448M	$8.029M
YoY Change	6.63%	6.18%	1.8%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.405M	$7.771M	$10.42M
Total Long-Term Liabilities	$8.561M	$8.448M	$8.029M
Total Liabilities	$15.97M	$16.22M	$18.45M
YoY Change	-13.45%	-22.15%	15.46%
SHAREHOLDERS EQUITY
Retained Earnings	-$36.46M	-$36.70M	-$38.07M
YoY Change	-4.23%	-7.97%	10.37%
Common Stock	$22.17K	$22.17K	$22.17K
YoY Change	0.0%	50.6%	50.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$15.75M	-$15.99M	-$15.62M
YoY Change
Total Liabilities & Shareholders Equity	$215.9K	$230.6K	$843.2K
YoY Change	-74.4%	-76.02%	-46.26%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q4
OPERATING ACTIVITIES
Net Income	$241.7K	$2.096M	$1.809M
YoY Change	-86.64%	-128.26%	-14.52%
Depreciation, Depletion And Amortization	$1.850K	$0.00	$4.100K
YoY Change	-54.88%	-100.0%	-85.77%
Cash From Operating Activities	-$185.8K	-$170.0K	-$235.9K
YoY Change	-21.24%	-1.95%	-54.36%
INVESTING ACTIVITIES
Capital Expenditures			$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities	$2.860K	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Cash From Investing Activities	$2.860K	$0.00	$0.00
YoY Change		-100.0%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	155.0K	110.0K	220.0K
YoY Change	-29.55%	-26.67%	-194.47%
NET CHANGE
Cash From Operating Activities	-185.8K	-170.0K	-235.9K
Cash From Investing Activities	2.860K	0.000	0.000
Cash From Financing Activities	155.0K	110.0K	220.0K
Net Change In Cash	-27.94K	-60.00K	-15.90K
YoY Change	75.72%	867.74%	-103.12%
FREE CASH FLOW
Cash From Operating Activities	-$185.8K	-$170.0K	-$235.9K
Capital Expenditures			$0.00
Free Cash Flow			-$235.9K
YoY Change			-53.3%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001530746
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2023Q3	us-gaap	Assets Held For Sale Not Part Of Disposal Group AssetsHeldForSaleNotPartOfDisposalGroup		usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable		usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2022Q3	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges		usd
	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges		usd
CY2023Q3	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness		usd
	kays	Lossgain On Debt Forgiveness LossgainOnDebtForgiveness		usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense		usd
	us-gaap	Increase Decrease In Deposits IncreaseDecreaseInDeposits		usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets		usd
	us-gaap	Proceeds From Sale Of Loans And Leases Held For Investment ProceedsFromSaleOfLoansAndLeasesHeldForInvestment		usd
	kays	Cash Paid For Impairment Of Rightofuse Asset CashPaidForImpairmentOfRightofuseAsset		usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	kays	Settlement Of Derivative Liabilites SettlementOfDerivativeLiabilites		usd
	kays	Adoption Of Lease Standard AdoptionOfLeaseStandard		usd
	kays	Initial Derivative Liability On Convertible Note Payable InitialDerivativeLiabilityOnConvertibleNotePayable		usd
CY2023Q3	kays	Atm Machine AtmMachine		usd
CY2023Q3	kays	Sign Amount SignAmount		usd
CY2022Q4	kays	Convertible Debt Two ConvertibleDebtTwo		usd
CY2022Q4	kays	Convertible Debt One ConvertibleDebtOne		usd
CY2023Q3	us-gaap	Capital Leases Future Minimum Payments Due In Rolling Year Three CapitalLeasesFutureMinimumPaymentsDueInRollingYearThree		usd
CY2023Q3	us-gaap	Capital Leases Future Minimum Payments Due In Rolling Year Four CapitalLeasesFutureMinimumPaymentsDueInRollingYearFour		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Entity File Number EntityFileNumber	333-177532
	dei	Entity Registrant Name EntityRegistrantName	KAYA HOLDINGS, INC
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	90-0898007
	dei	Entity Address Address Line1 EntityAddressAddressLine1	915 Middle River Drive
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 316
	dei	Entity Address City Or Town EntityAddressCityOrTown	Ft. Lauderdale
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33304
	dei	City Area Code CityAreaCode	(954)
	dei	Local Phone Number LocalPhoneNumber	892-6911
	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	22172835	shares
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	60268	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18330	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	13256	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	11990	usd
CY2023Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	49761	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	28158	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	123285	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	58478	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	19361	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	182604	usd
CY2022Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group AssetsHeldForSaleNotPartOfDisposalGroup	516076	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	217735	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	358396	usd
CY2023Q3	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	26785	usd
CY2022Q4	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	36720	usd
CY2023Q3	us-gaap	Alternative Investment AlternativeInvestment	21114	usd
CY2022Q4	us-gaap	Alternative Investment AlternativeInvestment	22188	usd
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	40005	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	27175	usd
CY2023Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	107265	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	784763	usd
CY2023Q3	us-gaap	Assets Assets	230550	usd
CY2022Q4	us-gaap	Assets Assets	843241	usd
CY2023Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	601154	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	961396	usd
CY2023Q3	us-gaap	Accounts Payable And Accrued Liabilities Fair Value Disclosure AccountsPayableAndAccruedLiabilitiesFairValueDisclosure	417777	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Fair Value Disclosure AccountsPayableAndAccruedLiabilitiesFairValueDisclosure	273190	usd
CY2023Q3	us-gaap	Interest Payable Current InterestPayableCurrent	2193	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1759669	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	21041	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	93067	usd
CY2023Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent	880062	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	876017	usd
CY2023Q3	kays	Convertible Notes Payable Net Of Discount Current ConvertibleNotesPayableNetOfDiscountCurrent	0	usd
CY2022Q4	kays	Convertible Notes Payable Net Of Discount Current ConvertibleNotesPayableNetOfDiscountCurrent	54707	usd
CY2023Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	25000	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	240293	usd
CY2023Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	109312	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	9312	usd
CY2023Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	3523317	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	6204878	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	7771028	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10417822	usd
CY2023Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	355000	usd
CY2023Q3	kays	Notes Payable Related Parties Noncurrent One NotesPayableRelatedPartiesNoncurrentOne	250000	usd
CY2022Q4	kays	Notes Payable Related Parties Noncurrent One NotesPayableRelatedPartiesNoncurrentOne	250000	usd
CY2023Q3	kays	Convertible Notes Payable Net Of Discount Non Current ConvertibleNotesPayableNetOfDiscountNonCurrent	69499	usd
CY2022Q4	kays	Convertible Notes Payable Net Of Discount Non Current ConvertibleNotesPayableNetOfDiscountNonCurrent	333107	usd
CY2023Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	7342653	usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	7179045	usd
CY2023Q3	kays	Accounts Payable And Accrued Liabilities Fair Value Disclosure Non Current AccountsPayableAndAccruedLiabilitiesFairValueDisclosureNonCurrent	500000	usd
CY2022Q4	kays	Accounts Payable And Accrued Liabilities Fair Value Disclosure Non Current AccountsPayableAndAccruedLiabilitiesFairValueDisclosureNonCurrent	500000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	100115	usd
CY2023Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	8447653	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	8029160	usd
CY2023Q3	us-gaap	Liabilities Liabilities	16218681	usd
CY2022Q4	us-gaap	Liabilities Liabilities	18446982	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22172835	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22172835	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22172835	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22172835	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	22173	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	22173	usd
CY2023Q3	us-gaap	Preferred Stock Shares Subscribed But Unissued Value PreferredStockSharesSubscribedButUnissuedValue	163630	usd
CY2022Q4	us-gaap	Preferred Stock Shares Subscribed But Unissued Value PreferredStockSharesSubscribedButUnissuedValue	163630	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	22478395	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	22277612	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-36703944	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-38071960	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-14538	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-11027	usd
CY2023Q3	kays	Stockholders Equity1 StockholdersEquity1	-14054284	usd
CY2022Q4	kays	Stockholders Equity1 StockholdersEquity1	-15619572	usd
CY2023Q3	us-gaap	Minority Interest MinorityInterest	-1933847	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-1984169	usd
CY2023Q3	kays	Stockholders Equity Including Portion Attributable To Noncontrolling Interest1 StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest1	-15988131	usd
CY2022Q4	kays	Stockholders Equity Including Portion Attributable To Noncontrolling Interest1 StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest1	-17603741	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	230550	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	843241	usd
CY2023Q3	us-gaap	Revenues Revenues	59011	usd
CY2022Q3	us-gaap	Revenues Revenues	172968	usd
	us-gaap	Revenues Revenues	162372	usd
	us-gaap	Revenues Revenues	556818	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	22088	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	59771	usd
	us-gaap	Cost Of Revenue CostOfRevenue	58402	usd
	us-gaap	Cost Of Revenue CostOfRevenue	182369	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	36923	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	113197	usd
	us-gaap	Gross Profit GrossProfit	103970	usd
	us-gaap	Gross Profit GrossProfit	374449	usd
CY2023Q3	us-gaap	Professional Fees ProfessionalFees	170405	usd
CY2022Q3	us-gaap	Professional Fees ProfessionalFees	182140	usd
	us-gaap	Professional Fees ProfessionalFees	563670	usd
	us-gaap	Professional Fees ProfessionalFees	565529	usd
CY2023Q3	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	44732	usd
CY2022Q3	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	94176	usd
	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	140871	usd
	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	296327	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	97916	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	106745	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	324750	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	380920	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	313053	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	383061	usd
	us-gaap	Operating Expenses OperatingExpenses	1029291	usd
	us-gaap	Operating Expenses OperatingExpenses	1242776	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-276130	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-269864	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-925321	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-868327	usd
CY2023Q3	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	165774	usd
CY2022Q3	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	158880	usd
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	484106	usd
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	466319	usd
CY2023Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	68762	usd
CY2022Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	6613	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	318315	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	163817	usd
CY2023Q3	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	219006	usd
	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	151082	usd
CY2022Q3	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	17177	usd
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	384429	usd
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	17177	usd
CY2023Q3	us-gaap	Increase Decrease In Derivative Assets And Liabilities IncreaseDecreaseInDerivativeAssetsAndLiabilities	2302249	usd
CY2022Q3	us-gaap	Increase Decrease In Derivative Assets And Liabilities IncreaseDecreaseInDerivativeAssetsAndLiabilities	-6994461	usd
	us-gaap	Increase Decrease In Derivative Assets And Liabilities IncreaseDecreaseInDerivativeAssetsAndLiabilities	2535936	usd
	us-gaap	Increase Decrease In Derivative Assets And Liabilities IncreaseDecreaseInDerivativeAssetsAndLiabilities	-3904639	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2377142	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-7142777	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2360949	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4517598	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	2101012	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-7412641	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	1435628	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-5385925	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5270	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	22535	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	19109	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	77398	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	2095742	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-7435176	usd
	us-gaap	Profit Loss ProfitLoss	1416519	usd
	us-gaap	Profit Loss ProfitLoss	-5463323	usd
CY2023Q3	us-gaap	Net Income Loss From Real Estate Investment Partnership Attributable To Noncontrolling Interest NetIncomeLossFromRealEstateInvestmentPartnershipAttributableToNoncontrollingInterest	62117	usd
CY2022Q3	us-gaap	Net Income Loss From Real Estate Investment Partnership Attributable To Noncontrolling Interest NetIncomeLossFromRealEstateInvestmentPartnershipAttributableToNoncontrollingInterest	-20279	usd
	us-gaap	Net Income Loss From Real Estate Investment Partnership Attributable To Noncontrolling Interest NetIncomeLossFromRealEstateInvestmentPartnershipAttributableToNoncontrollingInterest	48503	usd
	us-gaap	Net Income Loss From Real Estate Investment Partnership Attributable To Noncontrolling Interest NetIncomeLossFromRealEstateInvestmentPartnershipAttributableToNoncontrollingInterest	-78114	usd
CY2023Q3	kays	Profit Loss1 ProfitLoss1	2033625	usd
CY2022Q3	kays	Profit Loss1 ProfitLoss1	-7414897	usd
	kays	Profit Loss1 ProfitLoss1	1368016	usd
	kays	Profit Loss1 ProfitLoss1	-5385209	usd
CY2023Q3	kays	Basic Net Income Per Common Share BasicNetIncomePerCommonShare	0.09
CY2022Q3	kays	Basic Net Income Per Common Share BasicNetIncomePerCommonShare	-0.50
	kays	Basic Net Income Per Common Share BasicNetIncomePerCommonShare	0.06
	kays	Basic Net Income Per Common Share BasicNetIncomePerCommonShare	-0.37
CY2023Q3	kays	Weighted Average Number Of Common Shares Outstanding Basic WeightedAverageNumberOfCommonSharesOutstandingBasic	22172835	shares
CY2022Q3	kays	Weighted Average Number Of Common Shares Outstanding Basic WeightedAverageNumberOfCommonSharesOutstandingBasic	14722835	shares
	kays	Weighted Average Number Of Common Shares Outstanding Basic WeightedAverageNumberOfCommonSharesOutstandingBasic	22172835	shares
	kays	Weighted Average Number Of Common Shares Outstanding Basic WeightedAverageNumberOfCommonSharesOutstandingBasic	14722835	shares
CY2023Q3	kays	Diluted Net Income Per Common Share DilutedNetIncomePerCommonShare	0.00
CY2022Q3	kays	Diluted Net Income Per Common Share DilutedNetIncomePerCommonShare	0.00
	kays	Diluted Net Income Per Common Share DilutedNetIncomePerCommonShare	0.01
	kays	Diluted Net Income Per Common Share DilutedNetIncomePerCommonShare	-0.37
CY2023Q3	kays	Weighted Average Number Of Common Shares Outstanding Diluted WeightedAverageNumberOfCommonSharesOutstandingDiluted	143718093	shares
CY2022Q3	kays	Weighted Average Number Of Common Shares Outstanding Diluted WeightedAverageNumberOfCommonSharesOutstandingDiluted	14722835	shares
	kays	Weighted Average Number Of Common Shares Outstanding Diluted WeightedAverageNumberOfCommonSharesOutstandingDiluted	143718093	shares
	kays	Weighted Average Number Of Common Shares Outstanding Diluted WeightedAverageNumberOfCommonSharesOutstandingDiluted	14722835	shares
CY2023Q3	kays	Net Income Loss1 NetIncomeLoss1	2033625	usd
CY2022Q3	kays	Net Income Loss1 NetIncomeLoss1	-7414897	usd
	kays	Net Income Loss1 NetIncomeLoss1	1368016	usd
	kays	Net Income Loss1 NetIncomeLoss1	-5385209	usd
CY2023Q3	kays	Foreign Currency Adjustments ForeignCurrencyAdjustments	-2655	usd
CY2022Q3	kays	Foreign Currency Adjustments ForeignCurrencyAdjustments	-6162	usd
	kays	Foreign Currency Adjustments ForeignCurrencyAdjustments	-1692	usd
	kays	Foreign Currency Adjustments ForeignCurrencyAdjustments	-17900	usd
CY2023Q3	kays	Comprehensive Income Loss ComprehensiveIncomeLoss	2030970	usd
CY2022Q3	kays	Comprehensive Income Loss ComprehensiveIncomeLoss	-7421059	usd
	kays	Comprehensive Income Loss ComprehensiveIncomeLoss	1366324	usd
	kays	Comprehensive Income Loss ComprehensiveIncomeLoss	-5403109	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	62117	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	-20279	usd
	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	48503	usd
	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	-78114	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	1968853	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-7400780	usd
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	1317821	usd
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-5324995	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1368016	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5385209	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Noncontrolling Interest IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest	48503	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Noncontrolling Interest IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest	-78114	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	9935	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	17836	usd
	kays	Imputed Interests ImputedInterests	-16829	usd
	kays	Imputed Interests ImputedInterests	-16829	usd
	kays	Loss Gain On Impairment Of Rightofuse Asset LossGainOnImpairmentOfRightofuseAsset	-151082	usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	2535936	usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-3904639	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	318315	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	163817	usd
	kays	Lossgain On Debt Forgiveness LossgainOnDebtForgiveness	-91923	usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-384429	usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-17177	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	33963	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2145	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-22770	usd
	kays	Rightofuse Asset1 RightofuseAsset1	-45499	usd
	kays	Rightofuse Asset1 RightofuseAsset1	-71828	usd
	us-gaap	Increase Decrease In Deposits IncreaseDecreaseInDeposits	-12925	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	14679	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	433696	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	449490	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	14617	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	53272	usd
	kays	Accounts Payable And Accrued Expenses Related Parties AccountsPayableAndAccruedExpensesRelatedParties	144587	usd
	kays	Accounts Payable And Accrued Expenses Related Parties AccountsPayableAndAccruedExpensesRelatedParties	121995	usd
	kays	Rightofuse Liabilities1 RightofuseLiabilities1	-47322	usd
	kays	Rightofuse Liabilities1 RightofuseLiabilities1	-87546	usd
	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	4045	usd
	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	77398	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-855683	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-682851	usd
	us-gaap	Proceeds From Sales Of Assets Investing Activities ProceedsFromSalesOfAssetsInvestingActivities	693959	usd
	us-gaap	Proceeds From Sales Of Assets Investing Activities ProceedsFromSalesOfAssetsInvestingActivities	17177	usd
	us-gaap	Proceeds From Sale Of Loans And Leases Held For Investment ProceedsFromSaleOfLoansAndLeasesHeldForInvestment	193900	usd
	kays	Cash Paid For Impairment Of Rightofuse Asset CashPaidForImpairmentOfRightofuseAsset	-75000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	812859	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	17177	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	455000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	150000	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	370000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	85000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	150000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	42176	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-515674	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-238	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-9897	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18330	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	565979	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	60268	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	40408	usd
	us-gaap	Interest Paid Net InterestPaidNet	28582	usd
	kays	Settlement Of Derivative Liabilites SettlementOfDerivativeLiabilites	145625	usd
	kays	Adoption Of Lease Standard AdoptionOfLeaseStandard	23738	usd
	kays	Initial Derivative Liability On Convertible Note Payable InitialDerivativeLiabilityOnConvertibleNotePayable	110133	usd
	kays	Release Of Related Party Accruals And Payable ReleaseOfRelatedPartyAccrualsAndPayable	38329	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-14407905	usd
	kays	Imputed Interest ImputedInterest	11158	usd
	kays	Settlement Of Related Party Accrued Compensation SettlementOfRelatedPartyAccruedCompensation	52	usd
	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	-11738	usd
	us-gaap	Net Income Loss NetIncomeLoss	1971853	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-12436580	usd
CY2022Q3	kays	Imputed Interest ImputedInterest	5671	usd
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	-6162	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-7435176	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-19872247	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-17603741	usd
	kays	Imputed Interest ImputedInterest	11158	usd
	kays	Settlement Of Derivative Liabilities To Additional Paid In Capital SettlementOfDerivativeLiabilitiesToAdditionalPaidInCapital	145625	usd
	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	963	usd
	us-gaap	Net Income Loss NetIncomeLoss	-679223	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-18125218	usd
CY2023Q3	kays	Imputed Interest ImputedInterest	5671	usd
CY2023Q3	kays	Release Of Related Party Accruals And Payable ReleaseOfRelatedPartyAccrualsAndPayable	38329	usd
CY2023Q3	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	-2655	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	2095742	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-15988131	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80C_eus-gaap--NatureOfOperations_zgEZgjSonsN9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 –<span id="xdx_82B_zD6Evag3r2O9">ORGANIZATION AND NATURE OF THE BUSINESS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Organization</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kaya Holdings, Inc. FKA (Alternative Fuels Americas, Inc.) is a holding company. The Company was incorporated in 1993 and has engaged in a number of businesses. Its name was changed on May 11, 2007 to NetSpace International Holdings, Inc. (a Delaware corporation) (“NetSpace”). NetSpace acquired 100% of Alternative Fuels Americas, Inc. (a Florida corporation) in January 2010 in a stock-for-member interest transaction and issued 6,567,247 shares of common stock and 100,000 shares of Series C convertible preferred stock to existing shareholders. Certificate of Amendment to the Certificate of Incorporation was filed in October 2010 changing the Company’s name from NetSpace International Holdings, Inc. to Alternative Fuels Americas, Inc. (a Delaware corporation). Certificate of Amendment to the Certificate of Incorporation was filed in March 2015 changing the Company’s name from Alternative Fuels Americas, Inc. (a Delaware corporation) to Kaya Holdings, Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has four subsidiaries: Marijuana Holdings Americas, Inc., a Florida corporation (“MJAI”), which is majority-owned and was formed on March 27, 2014 to maintain ownership of the Company’s Oregon based cannabis operations, 34225 Kowitz Road, LLC, a wholly-owned Oregon limited liability company which held ownership of the Company’s 26 acre property in Lebanon, Oregon (inactive since Feb 28, 2023 when the subject property was sold), Kaya Brand International, Inc., a Florida Corporation (“KBI”) which is majority-owned and was formed on October 14, 2019 to expand the business overseas (active) and Fifth Dimension Therapeutics, Inc., a Florida corporation which is majority owned (“FTD”) and was formed on December 13, 2022 to develop and maintain ownership of the Company’s planned Psychedelic Clinics targeting Psilocybin and Ketamine Treatments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MJAI develops and operates the Company’s legal cannabis retail operations in Oregon through controlling ownership interests in five Oregon limited liability companies: MJAI Oregon 1 LLC (active), MJAI Oregon 2 LLC (inactive), MJAI Oregon 3 LLC (inactive) , MJAI Oregon 4 LLC (inactive) and MJAI Oregon 5 LLC (inactive).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MJAI Oregon 1 LLC is the entity that holds the licenses for the Company’s retail store operations. MJAI Oregon 5 LLC is the entity that held the license application for the Company’s 26 acre farm property in Lebanon Oregon (property sold 2/28/23, inactive since that date).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">KBI is the entity that holds controlling ownership interests in Kaya Farms Greece, S.A. (a Greek corporation) and Kaya Shalvah (“Kaya Farms Israel”, an Israeli corporation). These two entities were formed to facilitate expansion of the Company’s business in Greece and Israel respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fifth Dimension Therapeutics, Inc. (FTD) is the entity that was formed to hold interests in Psilocybin and Ketamine treatment facilities, with operations initially targeted for Oregon and Florida.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nature of the Business</b> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2014, KAYS incorporated MJAI, a wholly owned subsidiary, to focus on opportunities in the legal recreational and medical marijuana in the United States. MJAI has concentrated its efforts in Oregon, where through controlled Oregon limited liability companies, it initially secured licenses to operate a medical marijuana dispensary (an “MMD”) and following legalization of recreational cannabis use in Oregon, secured licenses to operate four retail outlets and purchased 26 acres for development as a legal cannabis cultivation and manufacturing facility. The Company has developed the Kaya Shack™ brand for its retail operations and the Kaya Farms ™ brand for its cannabis growing and processing operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 3, 2014 opened its first Kaya Shack™ MMD in Portland, Oregon. Between April of 2014 and December 31, 2022, KAYS owned and operated four (4) Kaya Shack™ retail cannabis medical and recreational dispensaries, three (3) Medical Marijuana Grow sites licensed by the OHA and two (2) Recreational Marijuana grow sites licensed by the OLCC (all in Oregon). The statuses of these operations are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The first Kaya Shack™ (Kaya Shack™ Store 1) opened in 2014 still maintains operations in Portland, Oregon at the same address as an Oregon Liquor and Cannabis Commission (OLCC) licensed medical and recreational marijuana retailer.</span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kaya Shack™ Store 2 was closed in December, 2022 as part of a sale and surrender agreement that the Company entered into with the OLCC to resolve an Administrative Action filed by the OLCC (as previously disclosed in the Company’s Annual Report on form 10-K for the period ending December 31, 2021 filed on April 18, 2022 and in the Company’s Quarterly report for the period ending March 31, 2022 filed on May 16, 2022). Per the terms of the agreement the Company agreed to either enter into a purchase and sale agreement for its retail license in South Salem by February 1, 2023 (the renewal date) or surrender the license. Since the time of the agreement the Company has entered into an asset purchase agreement for the sale of its receipt of approval from the Oregon Liquor Control and Cannabis Commission for the new licensee. On April 21, 2023 the Company concluded the sale of its Kaya Shack™ Store 2 Retail Cannabis Store (“Store 2”) for $210,000, less a 6% closing commission and minor closing expenses. After these expenses and paying $75,000 to resolve three non-performing store leases in South Oregon, the Company netted $118,900. The net book value of the assets as of December 31, 2022 was $0 and revenue for the year ended December 31, 2022 was approximately $410,880.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kaya Shack™ Store 3 and Kaya Shack™ Store 4 were both closed due to consolidation moves by the Company in 2020 and 2021, respectively, and the Company let the licenses lapse.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The three (3) Medical Marijuana Grows owned and operated by the Company through Oregon Health Authority (OHA) Licensure between 2015 and 2017 were all closed by the Company due to changing market conditions as OLCC Licensure of recreational marijuana came about and medical grow sites became economically unfeasible. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August of 2017, the Company purchased a 26-acre parcel in Lebanon, Linn County, Oregon for $510,000 on which we intended to construct a Greenhouse Grow and Production Facility (the “<b>Property</b>”) and filed for OLCC licensure. In August of 2022, the Company entered into an agreement (the “<b>CVC Agreement</b>”) with CVC International, Inc. (“<b>CVC</b>”), an institutional investor who holds certain of the Company’s Convertible Promissory Notes (the “<b>Notes</b>”), one of which was secured by a $500,000 mortgage on the Property. CVC released its lien on the Property to enable the Company to sell the Property and utilize the proceeds therefrom for the benefit of the Company and its shareholders, without having to repay CVC the $500,000 Note held by CVC. Additionally, CVC agreed to advance certain sums against the sale of the Property (“<b>Advances</b>”), which amounted to $270,000 pending the sale of the Property. On February 28, 2023 we sold the Property for a price of $770,312, less commissions and customary closing costs. The net proceeds of the sale were used to repay the advances plus interest (including an additional $100,000 borrowed from another lender interest) and the Company realized net proceeds of approximately $302,111. The land was reflected on the balance sheet as assets held for sale for the year ended December 31, 2022 and 2021, at a value of $516,076.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 18, 2018, the Company purchased the assets of Eugene, Oregon based Sunstone Farms which was licensed by the OLCC for cannabis production and processing. The purchase included a 12,000 square foot building housing and indoor grow facility, as well as equipment for growing and extraction activity. The purchase price of $1.3 was paid for by the issuance of 12 million shares of KAYS restricted stock, and the seller also purchased 2.5 million restricted shares for $250,000 in cash in a private transaction with the Company, and became a Board Member of Kaya Holdings. In mid-April, 2019 the OLCC filed an administrative proceeding proposing that the facility’s licenses (the “<b>Licenses</b>”) be cancelled, claiming that Sunstone had not filed paperwork correctly with respect to the transaction and the historical ownership of Bruce Burwick, the seller of the facility to the Company. Neither the Issuer nor any of its agents, consultants, employees or related entities was named as a respondent to the action. On March 31, 2021 the Company entered into a settlement with Sunstone and Burwick regarding the failure to deliver to KAYS the Licenses. Bruce Burwick surrendered to KAYS all 1,006,671 shares of our common stock issued to him in connection with the transaction (after adjustments for a 15:1 reverse split this was the 800,003 shares issued for the facility purchase, the 166,667 shares which were issued for $250,000 in cash and 40,001 shares which were issued as annual compensation for Burwick serving as a director of KAYS), and the Company received clear title to the warehouse facility. Burwick received $160,000 from the net proceeds of the sale of the facility's grow license to an unrelated third party, resigned from the Company's board of directors and agreed to work as a non-exclusive consultant to the Company for the next four years for a yearly fee of $35,000.00. On October 12, 2021, KAYS completed the sale of its Eugene, Oregon Cannabis Production and Processing Facility for gross proceeds of $1,325,000.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 26, 2019, the Company formed the majority owned subsidiary Kaya Brands International, Inc. (“KBI”) to serve as the Company’s vehicle for expansion into worldwide cannabis markets. Between September of 2019 and December 31, 2022 KBI has formed majority-owned subsidiaries in both Greece and Israel and its local operating subsidiaries have acquired interests in various licenses and entities as noted below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 7, 2020, Kaya Shalvah (“Kaya Farms Israel” or “KFI”), a majority owned subsidiary of KBI) was incorporated by the Company’s Israel Counsel. On March 30, 2021 the Company confirmed that its Israeli subsidiary, Kaya Shalvah has been awarded its initial license and permit from the "YAKAR", the Department for Medical Cannabis in the Israeli Ministry of Health, to develop an Israeli cannabis cultivation and processing facility. This initial license and permit grants Kaya Shalvah permission to proceed with its plans to develop commercial scale cannabis cultivation and processing in Israel. The license and permit are in good order and can be assigned to a location for development and licensure pending approval from the Yakar.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 27, 2020, Kaya Farms Greece, S.A. (“KFG”, a majority owned subsidiary of KBI) was incorporated by the Company’s Greek Counsel. On December 31, 2020, the Company entered into a joint venture agreement with Greekkannabis, PC (“GKC”, an Athens, Greece based cannabis company) and executed a formal agreement to acquire 50% of GKC which was completed in 2021. GKC has been issued two (2) Installation Licenses for construction of two medical cannabis cultivation and processing projects in Greece- one in Epidaurus, Greece and the other in Thebes, Greece. Neither of the subject properties are currently owned or optioned by GKC or its operating subsidiaries, but the land for the potential project in Epidaurus is owned by one of the Greek Partner’s families and the Land in Thibes is currently available for purchase or option and the Company believes it could acquire either of the Properties once funding and market conditions allow. Alternatively, both licenses are in good order, and can be transferred to a new location pending Greek Government approval.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 13, 2022, the Company formed Fifth Dimension Therapeutics <span style="color: #444444; background-color: white">™ </span>(“FTD”, a Florida Corporation) to seek to provide psychedelic services to sufferers of treatment resistant mental health diseases such as depression, PTSD and other mental health disorders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 3, 2023 the Oregon Health Authority (the “OHA”) began to accept license applications, allowing each entity to own and operate one (1) Psilocybin manufacturing and processing facility for the production of Psilocybin Mushrooms and derived therapeutics (“Psilocybins”), and up to five (5) Psilocybin Facilitation Centers where clients would go to ingest Psilocybins and experience effects under the supervision of State Licensed Facilitators.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The OHA also launched Oregon’s medical cannabis program in 2014, giving KAYS critical experience in comprehending and complying with OHA mandates. The psilocybin opportunity is a logical extension for Kaya Holdings. The purpose, customer, regulations, and operations, as well as our familiarity with Oregon regulators, are synergistic with our current mission, and can be leveraged within our current operational infrastructure. We anticipate being able to respond to market demand rapidly, upon licensing. The licenses to be issued in Oregon will be the first ever State Legal Licensing of Psilocybin Manufacturing and Treatment Centers, and KAYS is positioned to be a first mover due to its operating history in Oregon. The Company has begun the process of enrolling staff that qualify for the licensing into the training programs that have been approved for state certification and is in process of identifying a site for Psilocybin Manufacturing and Processing and up to five (5) sites to open and operate Psilocybin Facilitation Centers, subject to financing and final regulatory approval.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On January 25, 2023 the Company confirmed that attorney Glenn E.J. Murphy was welcomed as a founding member to the FDT Board of Directors. Glenn will assist FDT with introductions to pharmaceutical companies seeking data and access to psychedelic patients, as well as advising on the development of intellectual property, structure of potential joint ventures, funding opportunities, acquisitions, and other related endeavors. Glenn has twenty-five years of private and corporate practice, including ten years in-house with the Henkel Group and more than fifteen years in private practice, Glenn's experience has touched on most every aspect of intellectual property practice.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 13, 2023, Bryan Arnold (one of KAYS Vice Presidents and its longest serving Oregon Employee) completed his OHA Certified Psilocybin Education through the Changra Institute and became one of the first eighteen graduates to obtain Psilocybin Facilitator certification in the State of Oregon. Bryan’s Facilitation License application has been approved by the OHA, and he now may oversee up to five (5) Psilocybin Treatment Facilities and up to one (1) Psilocybin Production Facility. Additionally, the Company expects to enroll additional potential licensee candidates within the coming months to bolster its ranks of OHA Licensed Psilocybin Facilitators as it moves forward with plans to open its first Psilocybin Clinic, subject to completion of financing and regulatory approvals.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0.05in 0 0; text-align: justify">On November 14, 2023 the Company filed a license application with the Oregon Department of Health (the “<b>OHA</b>”) for the licensure of The Sacred Mushroom™, an approximately 11,000 square foot <span style="background-color: white">psilocybin treatment center </span>located in Portland, Oregon which would serve as the Company’s flagship psilocybin facility.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 15, 2023 KAYS reached an agreement in principle with Florida-based Total Holistic Center™ ("Total Holistic") to assist FDT with the development of its ketamine treatment model as a first step in the launch of its planned Fifth Dimension Therapeutics Mind Care Clinics and Telehealth Services. The Company has not yet proceeded with any further work to open ketamine clinics as it instead elected to concentrate on opening a Psilocybin Treatment Service Center in Portland, Oregon.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 4pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	kays	Net Income NetIncome	1368016	usd
	kays	Net Loss NetLoss	5385209	usd
CY2023Q3	kays	Working Capital Deficiency WorkingCapitalDeficiency	7647743	usd
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_84F_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zfMuM6ORWzp5" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zawoH9O6hEU9">Reclassifications</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior period amounts have been reclassified to conform to the current period presentation.</span></p>
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_842_eus-gaap--UseOfEstimates_zSmpaL39nuy1" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zShZ3qDuMIpi">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such estimates and assumptions impact both assets and liabilities, including but not limited to: net realizable value of accounts receivable and inventory, estimated useful lives and potential impairment of property and equipment, the valuation of intangible assets, estimate of fair value of share based payments and derivative liabilities, estimates of fair value of warrants issued and recorded as debt discount, estimates of tax liabilities and estimates of the probability and potential magnitude of contingent liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate could change in the near term due to one or more future non-conforming events. Accordingly, actual results could differ significantly from estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_849_eus-gaap--ConcentrationRiskCreditRisk_zmpJQDjLLfc6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zph5JbbPq4n2">Risks and Uncertainties</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s operations are subject to risk and uncertainties including financial, operational, regulatory and other risks including the potential risk of business failure. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has experienced, and in the future expects to continue to experience, variability in its sales and earnings. The factors expected to contribute to this variability include, among others, (i) the uncertainty associated with the commercialization and ultimate success of the product, (ii) competition inherent at other locations where product is expected to be sold (iii) general economic conditions and (iv) the related volatility of prices pertaining to the cost of sales. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Fiscal Period FiscalPeriod	<p id="xdx_841_eus-gaap--FiscalPeriod_zxtAf9dmBeb6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zWmsNoOJGR51">Fiscal Year</span> </b>The Company’s fiscal year-end is December 31.</span></p> <p style="font: 4pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	13256	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	11990	usd
CY2023Q3	kays	Inventory Allowance And Impairment InventoryAllowanceAndImpairment	0	usd
CY2022Q4	kays	Inventory Allowance And Impairment InventoryAllowanceAndImpairment	0	usd
CY2022Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	42965	usd
CY2023Q3	kays	Plant Property PlantProperty	25000	usd
CY2022Q4	kays	Plant Property PlantProperty	44430	usd
	us-gaap	Revenue Recognition Leases Operating RevenueRecognitionLeasesOperating	<p id="xdx_845_eus-gaap--RevenueRecognitionLeasesOperating_zzazes7bTgXf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_z5IUhsVSRtth">Operating Leases</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We lease our retail stores under non-cancellable operating leases. Most store leases include tenant allowances from landlords, rent escalation clauses and/or contingent rent provisions. We recognize rent expense on a straight-line basis over the lease term, excluding contingent rent, and record the difference between the amount charged to expense and the rent paid as a deferred rent liability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3	us-gaap	Land Land	17703	usd
	us-gaap	Derivatives Reporting Of Derivative Activity DerivativesReportingOfDerivativeActivity	<p id="xdx_848_eus-gaap--DerivativesReportingOfDerivativeActivity_znsbnaLZvE56" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_z8kzZQcBR0dc">Derivative Financial Instruments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. For option-based simple derivative financial instruments, the Company uses the Binomial option-pricing model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2017, the FASB issued ASU 2017-11 <i>Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivative and Hedging (Topic 815).</i> The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendment also clarifies existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (“EPS”) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt-Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior to this Update, an equity-linked financial instrument with a down round feature that otherwise is not required to be classified as a liability under the guidance in Topic 480 is evaluated under the guidance in Topic 815, Derivatives and Hedging, to determine whether it meets the definition of a derivative. If it meets that definition, the instrument (or embedded feature) is evaluated to determine whether it is indexed to an entity’s own stock as part of the analysis of whether it qualifies for a scope exception from derivative accounting. Generally, for warrants and conversion options embedded in financial instruments that are deemed to have a debt host (assuming the underlying shares are readily convertible to cash or the contract provides for net settlement such that the embedded conversion option meets the definition of a derivative), the existence of a down round feature results in an instrument not being considered indexed to an entity’s own stock. This results in a reporting entity being required to classify the freestanding financial instrument or the bifurcated conversion option as a liability, which the entity must measure at fair value initially and at each subsequent reporting date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 4pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amendments in this Update revise the guidance for instruments with down round features in Subtopic 815-40, Derivatives and Hedging—Contracts in Entity’s Own Equity, which is considered in determining whether an equity-linked financial instrument qualifies for a scope exception from derivative accounting. An entity still is required to determine whether instruments would be classified in equity under the guidance in Subtopic 815-40 in determining whether they qualify for that scope exception. If they do qualify, freestanding instruments with down round features are no longer classified as liabilities and embedded conversion options with down round features are no longer bifurcated.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For entities that present EPS in accordance with Topic 260, and when the down round feature is included in an equity-classified freestanding financial instrument, the value of the effect of the down round feature is treated as a dividend when it is triggered and as a numerator adjustment in the basic EPS calculation. This reflects the occurrence of an economic transfer of value to the holder of the instrument, while alleviating the complexity and income statement volatility associated with fair value measurement on an ongoing basis. Convertible instruments are unaffected by the Topic 260 amendments in this Update.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amendments in Part 1 of this Update are a cost savings relative to former accounting. This is because, assuming the required criteria for equity classification in Subtopic 815-40 are met, an entity that issued such an instrument no longer measures the instrument at fair value at each reporting period (in the case of warrants) or separately accounts for a bifurcated derivative (in the case of convertible instruments) on the basis of the existence of a down round feature. For convertible instruments with embedded conversion options that have down round features, applying specialized guidance such as the model for contingent beneficial conversion features rather than bifurcating an embedded derivative also reduces cost and complexity. Under that specialized guidance, the issuer recognizes the intrinsic value of the feature only when the feature becomes beneficial instead of bifurcating the conversion option and measuring it at fair value each reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amendments in Part II of this Update replace the indefinite deferral of certain guidance in Topic 480 with a scope exception. This has the benefit of improving the readability of the Codification and reducing the complexity associated with navigating the guidance in Topic 480.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company adopted this new standard on January 1, 2019; however, the Company needs to continue the derivative liabilities due to variable conversion price on some of the convertible instruments. As such, it did not have a material impact on the Company’s consolidated financial statements. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	30713	usd
CY2022Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	30713	usd
CY2023Q3	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	59733	usd
CY2022Q4	kays	Atm Machine AtmMachine	5600	usd
CY2022Q4	us-gaap	Land Land	17702	usd
CY2023Q3	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	32304	usd
CY2022Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	147636	usd
CY2023Q3	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	55067	usd
CY2022Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	69312	usd
CY2022Q4	kays	Sign Amount SignAmount	12758	usd
CY2023Q3	us-gaap	Capitalized Costs Support Equipment And Facilities CapitalizedCostsSupportEquipmentAndFacilities	24000	usd
CY2022Q4	us-gaap	Capitalized Costs Support Equipment And Facilities CapitalizedCostsSupportEquipmentAndFacilities	24000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	244520	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	395116	usd
CY2023Q3	kays	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment1 AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment1	217735	usd
CY2022Q4	kays	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment1 AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment1	358396	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	26785	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	36720	usd
CY2023Q3	us-gaap	Time Deposits Noncurrent TimeDepositsNoncurrent	23941	usd
CY2022Q4	us-gaap	Time Deposits Noncurrent TimeDepositsNoncurrent	11016	usd
CY2023Q3	us-gaap	Deposits Assets DepositsAssets	5491	usd
CY2022Q4	us-gaap	Deposits Assets DepositsAssets	5491	usd
CY2023Q3	us-gaap	Receivables Net Current ReceivablesNetCurrent	10573	usd
CY2022Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	10668	usd
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	40005	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	27175	usd
CY2023Q3	kays	Total Convertible Debt TotalConvertibleDebt	7437152	usd
CY2022Q4	kays	Total Convertible Debt TotalConvertibleDebt	7807152	usd
CY2023Q3	kays	Convertible Notes Payable Long Term Net Of Discounts ConvertibleNotesPayableLongTermNetOfDiscounts	-69499	usd
CY2022Q4	kays	Convertible Notes Payable Long Term Net Of Discounts ConvertibleNotesPayableLongTermNetOfDiscounts	-387819	usd
CY2023Q3	kays	Convertible Notes Payable Net Of Discount ConvertibleNotesPayableNetOfDiscount	7367653	usd
CY2022Q4	kays	Convertible Notes Payable Net Of Discount ConvertibleNotesPayableNetOfDiscount	7419333	usd
CY2023Q3	kays	Convertible Debt Net Of Discounts Current ConvertibleDebtNetOfDiscountsCurrent	25000	usd
CY2022Q4	kays	Convertible Debt Net Of Discounts Current ConvertibleDebtNetOfDiscountsCurrent	240288	usd
CY2023Q3	us-gaap	Convertible Debt ConvertibleDebt	7342653	usd
CY2022Q4	us-gaap	Convertible Debt ConvertibleDebt	7179045	usd
CY2023Q3	kays	Convertible Debt Note Five ConvertibleDebtNoteFive	9312	usd
CY2022Q4	kays	Convertible Debt Note Five ConvertibleDebtNoteFive	9312	usd
CY2023Q3	kays	Convertible Debt Two ConvertibleDebtTwo	355000	usd
CY2023Q3	kays	Convertible Debt One ConvertibleDebtOne	100000	usd
CY2023Q3	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	464312	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	9312	usd
CY2023Q3	us-gaap	Loans Payable LoansPayable	250000	usd
CY2022Q4	us-gaap	Loans Payable LoansPayable	250000	usd
CY2023Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	22172835	shares
	kays	Derivative Liabilities Text Bock DerivativeLiabilitiesTextBock	<p id="xdx_806_ecustom--DerivativeLiabilitiesTextBock_zxoySKSPrxol" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 10 –<span id="xdx_82C_zrjvLdX1KLAa">DERIVATIVE LIABILITIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective January 1, 2019, an equity-linked financial instrument with a down round feature that otherwise is not required to be classified as a liability under the guidance in Topic 480 is evaluated under the guidance in Topic 815, Derivatives and Hedging, to determine whether it meets the definition of a derivative. If it meets that definition, the instrument (or embedded feature) is evaluated to determine whether it is indexed to an entity’s own stock as part of the analysis of whether it qualifies for a scope exception from derivative accounting. Generally, for warrants and conversion options embedded in financial instruments that are deemed to have a debt host (assuming the underlying shares are readily convertible to cash or the contract provides for net settlement such that the embedded conversion option meets the definition of a derivative), the existence of a down round feature results in an instrument not being considered indexed to an entity’s own stock. This results in a reporting entity being required to classify the freestanding financial instrument or the bifurcated conversion option as a liability, which the entity must measure at fair value initially and at each subsequent reporting date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">However, due to a recognition of tainting, due to variable conversion price on some of the convertible notes, all convertible notes are considered to have a derivative liability, therefore the Company accounted for these Notes under ASC Topic 815-15 “Embedded Derivative.” The derivative component of the obligation is initially valued and classified as a derivative liability with an offset to discounts on convertible debt. Discounts are amortized to interest expense over the respective term of the related note. In determining the indicated value of the convertible note issued, the Company used the Binomial Options Pricing Model with a risk-free interest rate of ranging 5.03% to 5.53%, volatility ranging from 149.93% to 194.43%, trading prices was $0.045 per share and a conversion price ranging from $0.04 to $0.08 per share. The total derivative liabilities associated with these notes were $3,523,317 at September 30, 2023 and $6,204,878 at December 31, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of the application of ASC No. 815, the fair value of the ratchet feature related to convertible debt and warrants is summarized as follow: </span></p> <p id="xdx_891_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zYMhJ5OSU4pc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zsD5GDBiBCe4" style="display: none">Schedule Of Derivative Liabilities At Fair Value</span> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_303_134_z1uC7Oc9vsN3" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - DERIVATIVE LIABILITIES (Details)"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="3" id="xdx_492_20230101__20230930_zjcuwm44gLZg" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_ecustom--DerivativeAssetsLiabilities_z04spUhakWoe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance as of December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,204,878</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_407_ecustom--InitialDerivativeLiabilities_zaFJ80rfN6rf" style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in Derivative Values</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,535,936</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_409_ecustom--SettlementOfDebtreclass_zV9cpF4HDqea" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Settlement of debt-reclass to APIC</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(145,625</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_408_ecustom--DerivativeAssetsLiabilitiesEnding_z8swvgtmCvZ8" style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance as of September 30, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,523,317</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A6_zsExTL6mjk1k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recorded the debt discount to the extent of the gross proceeds raised and expended immediately the remaining fair value of the derivative liability, as it exceeded the gross proceeds of the note. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recorded settlement of debt, reclassed to APIC of $<span id="xdx_900_eus-gaap--SettlementLiabilitiesCurrent_iI_c20230930_zeghKCAHpBUk" title="Settlement Debt">145,625</span> and $<span id="xdx_90C_eus-gaap--SettlementLiabilitiesCurrent_iI_c20220930_zp6c0MZ5upIe" title="Settlement of debt">0</span> for the nine months ended September 30, 2023 and 2022, respectively. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recorded a change in the value of embedded derivative liabilities gain of $<span id="xdx_90E_eus-gaap--EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_iI_c20230930_zTz3O0bXfD95" title="Embedded derivative liabilities gain">2,535,936</span> and a loss of $<span id="xdx_90B_eus-gaap--EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_iI_c20220930_z0ByAQMgFkFa" title="Embedded derivative liabilities gain">3,904,639</span> for the nine months ended September 30, 2023 and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	kays	Derivative Assets Liabilities DerivativeAssetsLiabilities	6204878	usd
	kays	Initial Derivative Liabilities InitialDerivativeLiabilities	-2535936	usd
	kays	Settlement Of Debtreclass SettlementOfDebtreclass	-145625	usd
	kays	Derivative Assets Liabilities Ending DerivativeAssetsLiabilitiesEnding	3523317	usd
CY2023Q3	us-gaap	Settlement Liabilities Current SettlementLiabilitiesCurrent	145625	usd
CY2022Q3	us-gaap	Settlement Liabilities Current SettlementLiabilitiesCurrent	0	usd
CY2023Q3	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	2535936	usd
CY2022Q3	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	3904639	usd
CY2023Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	69499	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	387819	usd
	kays	Amortization Of Financing Costs And Discount AmortizationOfFinancingCostsAndDiscount	318320	usd
	kays	Amortization Of Financing Costs And Discount AmortizationOfFinancingCostsAndDiscount	163817	usd
CY2022	kays	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Terms1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerms1	0.36
CY2022	kays	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Terms2 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerms2	0.36
CY2023Q3	us-gaap	Capital Leases Future Minimum Payments Next Rolling Twelve Months CapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths	9300	usd
CY2023Q3	us-gaap	Capital Leases Future Minimum Payments Due In Rolling Year Two CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo	12400	usd
CY2023Q3	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	21700	usd
CY2023Q3	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	659	usd
CY2023Q3	us-gaap	Capital Leased Assets Gross CapitalLeasedAssetsGross	21041	usd

Files In Submission

Name	View Source	Status
0001903596-23-000916-index-headers.html	Edgar Link	pending
0001903596-23-000916-index.html	Edgar Link	pending
0001903596-23-000916.txt	Edgar Link	pending
0001903596-23-000916-xbrl.zip	Edgar Link	pending
ex31_1.htm	Edgar Link	pending
ex32_1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
image_006.jpg	Edgar Link	pending
image_007.jpg	Edgar Link	pending
image_008.jpg	Edgar Link	pending
image_009.jpg	Edgar Link	pending
image_010.jpg	Edgar Link	pending
image_011.jpg	Edgar Link	pending
image_012.jpg	Edgar Link	pending
image_013.jpg	Edgar Link	pending
image_014.jpg	Edgar Link	pending
image_015.jpg	Edgar Link	pending
image_016.jpg	Edgar Link	pending
image_017.jpg	Edgar Link	pending
image_018.jpg	Edgar Link	pending
image_019.jpg	Edgar Link	pending
kays-20230930.xsd	Edgar Link	pending
kays_10q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
kays-20230930_cal.xml	Edgar Link	unprocessable
kays-20230930_lab.xml	Edgar Link	unprocessable
kays-20230930_def.xml	Edgar Link	unprocessable
kays-20230930_pre.xml	Edgar Link	unprocessable
kays_10q_htm.xml	Edgar Link	completed
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$KAYS
Kaya Holdings Inc Stock $kays

2023 Q4 Form 10-Q Financial Statement

#000190359623000916 Filed on November 20, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KAYS Kaya Holdings Inc Stock $kays

2023 Q4 Form 10-Q Financial Statement

#000190359623000916 Filed on November 20, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KAYS
Kaya Holdings Inc Stock $kays